The North America Point of Care Molecular Diagnostics Market is projected to reach a revenue of 4,100 Million USD in 2025, up from 2,100 Million USD in 2020. The market is forecast to grow steadily, culminating at approximately 9,300 Million USD by 2035, reflecting a CAGR of about 8.2% during the forecast period. This robust trajectory is powered by rapid adoption of innovative POCT technologies across healthcare settings, ongoing investments in R&D, and the continuous need for decentralized diagnostic solutions to manage public health threats.

Read More - https://bussinessinsights.com/research-report/north-america-point-of-care-molecular-diagnostics-market

In 2025, Infectious Diseases continue to drive the majority share in Point of Care Molecular Diagnostics applications, accounting for 46% of the segment due to the persistent threat of viral outbreaks and increasing attention to antimicrobial resistance. Oncology represents 17%, buoyed by innovations in rapid tumor marker detection, while Prenatal Testing holds a noteworthy 13% market share. The ease and speed of point-of-care solutions make them increasingly relevant for Hematology and Endocrinology, though these remain secondary to the leading segments. The diverse clinical utility of POCT amplifies its role in delivering timely and accurate diagnostic information across multiple care settings.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-point-of-care-molecular-diagnostics-market

Frequently Asked Questions

Who are the key players in North America Point of Care Molecular Diagnostics Market industry?
The top five players in the North America Point of Care Molecular Diagnostics Market are Abbott Laboratories, Roche Diagnostics, Cepheid (Danaher Corporation), BioMérieux SA, and Hologic Inc. These companies lead the market due to their innovative diagnostic platforms, strong product portfolios, and expanding distribution networks across the region.

What is the North America Point of Care Molecular Diagnostics Market growth?
The North America Point of Care Molecular Diagnostics Market is experiencing robust growth, propelled by rising demand for rapid infectious disease testing. Abbott Laboratories reported a surge in molecular testing revenues due to accelerated adoption during the COVID-19 pandemic, underscoring a sustained positive outlook for the sector.

Which segment accounted for the largest North America Point of Care Molecular Diagnostics Market share?
The infectious diseases segment holds the largest share in the North America Point of Care Molecular Diagnostics Market. This dominance is attributed to the high prevalence of diseases like influenza, RSV, and HIV, and the growing preference for rapid, accurate tests in clinical and outpatient settings.

Thanks & Regards,
Priya
sales@bussinessinsights.com